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Abstract
Background: Colon cancer is invariably accompanied by altered coagulation activity; however, the precise role of
phosphatidylserine (PS) in the hypercoagulable state of colon cancer patients remains unclear. We explored the exposure
of PS on platelets and microparticles (MPs), and evaluate its role in procoagulant activity in colon cancer patients.
Methods: PS-positive platelets and MPs, mainly from platelets and endothelial cells, were detected by flow cytometry
and confocal microscopy, and their procoagulant activity was assessed with purified coagulation complex assays,
clotting time, and fibrin turbidity.
Results: Plasma levels of PS-positive platelets increased gradually from stage I to IV and were higher in all stages of the
patients than in the healthy control, while PS-positive platelet-derived MPs only increased significantly in stage III/IV
patients. Meanwhile, PS-positive MPs and endothelial-derived MPs in stage II/III/IV patients were markedly higher than
ones in controls but no difference with stage I. Tissue factor positive MPs were higher in all 4 stages of colon cancer
patients than in the healthy control. Platelets and MPs from the patients demonstrated significantly enhanced intrinsic/
extrinsic FXa and thrombin generation, greatly shortened coagulation time, and increased fibrin formation. Combined
treatment with PS antagonist lactadherin, strongly prolonged the coagulation time and reduced fibrin formation by
inhibiting factor tenase and prothrombinase complex activity. In contrast, pretreatment with anti tissue factor antibody
played a lesser role in suppression of procoagulant activity.
Conclusion: Our results suggest that PS-positive platelets and MPs contribute to hypercoagulability and represent a
potential therapeutic target to prevent coagulation in patients with colon cancer.
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Background
Colorectal cancer is the most common gastrointestinal
cancer and the second cause of cancer death worldwide,
with the incidence of colon cancer increasing in most
countries over the past 20 years [1, 2]. Thrombotic dis-
orders including venous thromboembolism, a life-
threatening complication, were frequently observed in
patients with colon cancer [3, 4] . Previous studies have
demonstrated the development of a hypercoagulable
state in colon cancer patients with elevated markers of
coagulation, including thrombin-antithrombin complex,
prothrombin fragment 1 + 2, soluble fibrin, and total fi-
brin(ogen) degradation products fibrinogen [5, 6]. How-
ever, relatively little is known about the mechanism of
this increased procoagulant activity (PCA) in those pa-
tients. Increased activity of the coagulation cascade and
decreased activity of coagulation inhibitors (e.g., tissue
factor pathway inhibitor) at the colon cancer site were
also demonstrated [7, 8]. Nevertheless, circulating cells
or other factors that are associated with this hypercoagu-
lable state in colon cancer have not been well
determined.
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Phosphatidylserine (PS), on the surface of activated
platelets, confers a procoagulant surface necessary for
hemostasis by providing binding sites for both intrinsic
and extrinsic FXa and the assembly of prothrombinase
complexes to generate thrombin, resulting in fibrin for-
mation [9, 10]. Others and our previous studies have
shown that elevated PS exposure on circulating platelets
plays a critical role in the thrombotic risk associated dis-
orders, including chronic uremia, nephrotic syndrome,
and polycythemia vera [11–13]. Platelet hyperactivation
has been observed in colon cancer and is indicated to be in-
volved in the cancer progression [14–16]. However, relatively
little is known about to what extent PS exposed on platelets,
or whether PS+ platelets contribute to over-exuberant co-
agulation in different stage of colon cancer patients.
PS express at the surface of circulating microparticles
(MPs), which are small vesicular structures (0.1-1 μm
diameter) produced and released by exocytic blebbing of
the activated cell plasma membrane from a variety of
cell types such as platelets and endothelial cells [17, 18].
Although there have been study using annexin V as a
probe to detect PS+ MPs in colon cancer patients [19],
inhibition assays were not performed to clarify whether
PS+ MPs are responsible for MP-associated PCA. Studies
also implicated that tissue factor (TF) may be the pivotal
source for the generation of MP and increased TF activ-
ity of MP has been inducted in colon cancer patients
[19, 20]. However, exposed TF is generally quiescent un-
less it resides in a membrane containing PS [21]. The
relative contributions of TF and PS to coagulation acti-
vation in colon cancer patients remain to be established.
Our previous study have demonstrated that lactadherin
was a more sensitive probe than annexin V for the detec-
tion of PS exposure on circulating cells or MPs, and it
could be an anticoagulant to abrogate activation of the co-
agulation cascade both in vitro and vivo [22–24]. There-
fore, we used lactadherin to quantify and further analyzed
PS+ platelets and MPs in different stage of colon cancer
patients. We defined the intrinsic and extrinsic FXa, and
thrombin generation, coagulation time, and fibrin forma-
tion of the PS+ platelets and MPs in the study subjects.
Lactadherin and anti-TF antibody was used to inhibit the
PCA of the platelets and MPs. The current study enables
us to better understand the mechanism of hypercoagula-
ble state in colon cancer patients.
Methods
Patients
From October 2014 to November 2015, 112 colon can-
cer patients, admitted to the First Hospital of Harbin
Medical University, were enrolled in the study. Patients
were all diagnosed with colon cancer by pathological ex-
aminations through colonoscopy. Then blood samples of
diagnosed patients were collected before the operation
and chemotherapy for experiments. Those who needed
surgical operation were further diagnosed by patho-
logical examinations during surgical operation to clarify
whether those two results were consistent. Patients who
had previously received anticoagulation or antiplatelet
therapy such as aspirin, or had a history of coagulation
or hemorrhage complications within three months were
excluded from the study. Other exclusion criteria in-
cluded diabetes, hypertension, malignant or systemic
disease, pregnancy, active or chronic infection, blood
transfusion within the past six months. The patient
group consisted of 55 males and 57 females, with ages
ranging from 36 to 83 years. The disease stage for the
patients was confirmed according to cancer staging cri-
teria of the 7th edition staging American Joint Commit-
tee on Cancer (AJCC) [25]. The control group was
composed of 33 healthy blood donor volunteers (17
males and 16 females). They were chosen from routine
health examinations based on the following selection cri-
teria: all physical indicators were in the normal range
and the volunteers were free of cancer, hepatitis, or in-
fection, among others. Characteristics of all the study
subjects are shown in Table 1. The protocols and proce-
dures were approved by the Harbin Medical University
research ethics committee and were based on the guid-
ing policy, and informed consent was obtained from all
participants.
Materials
Calibrated polystyrene latex beads (1.0 μm) were from
Sigma (UK). Trucount Tube (Cat. No. 340334), purified
CD31 (clone L133.1), CD41a (clone HIP8), CD142 (clone
HFT-1), and mouse IgG1/IgG2a (clone X40/X39) were
from Becton Dickinson Biosciences (San Jose, CA, USA).
All monoclonal antibodies were labelled in our laboratory
with Alexa Fluro 647 or Alexa Fluro 488. Polyclonal anti-
body against human Tissue Factor (product No. 4502)
was from American Diagnostica Inc. (Stamford, CT,
USA). Alexa Fluro 647-conjugated lactadherin were
prepared in our laboratory. Human factors Va, VIIa,
VIII, IXa, X, Xa, prothrombin and thrombin were all
from Haematologic Technologies (Burlington, VT,
USA). Mouse anti-fibrin II chain (clone NYBT2G1) was
from Accurate Chemical & Scientific (Westbury, NY, USA).
Isotype control antibody was from Dako (Carpinteria, CA,
USA). Tyrode’s buffer containing 1 mM Hepes was consti-
tuted in our laboratory and was filtered through a 0.22 μm
syringe filter from Millipore (UK). Chromogenic substrates
S-2765 and S-2238 were from DiaPharma Group (West
Chester, OH, USA).
Protein purification and labeling
Lactadherin was purified from bovine milk and labeled
with Alexa Fluor 647 or Alexa Fluor 488 as described
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previously. The ratio of fluorescein to lactadherin was
1.2/1 or 1.1/1 [24] .
Blood collection, preparation of platelets and MPs
Blood was drawn before therapy with a 21-gauge needle
and was collected into a 5-mL tube containing 3.2 % cit-
rate (BD, Plymouth, UK). Platelet-rich plasma (PRP) was
prepared within 30 min (min) of blood collection by
centrifugation for 13 min, 200 g at room temperature,
and was analyzed immediately after isolation. Platelet-
free plasma (PFP) was prepared as described [13, 26].
Briefly, samples were centrifuged for 20 min at 1,500 g,
and plasma was harvested and re-centrifuged for 2 min
at 13,000 g to remove all residual platelets. PFP were
snap-frozen in liquid nitrogen, and then stored at −80 °C
until use. In order to isolate the MPs, 250 μl of PFP was
thawed on ice for 60 min and then centrifuged at
20,000 g for 45 min at 20 °C [13, 27]. Subsequently,
225 μl of supernatant (i.e. MP-free plasma) was aspirated
and the remaining 25 μL MPs pellet was washed once
by centrifugation and resuspended in 75 μl of Tyrode’s
buffer (MP enriched suspension).
Flow cytometric analysis of PS exposure on platelets
The exposure of PS on platelets was measured using lac-
tadherin binding by flow cytometry. Platelets were ad-
justed to (0.5-1) × 106/ml in a final volume of 200 μl
with Tyrode’s buffer; five μl of Alexa 488-conjugated lac-
tadherin was added to the cell suspension and incubated
for 10 min at room temperature in the dark. Five
thousand events per sample were acquired and analyzed
with BD FACS Diva Software.
Flow cytometric analysis of PS exposure on MPs
MPs were identified as described previously [13]. Plate-
let, endothelial and tissue factor (TF)-derived MPs were
defined as smaller than 1 μm and lactadherin+ CD41a+,
lactadherin+ CD31+CD41a− and lactadherin+ CD142+,
respectively. The number of each MP type per μl was
calculated by Trucount Tube (with a precise number of
fluorescent beads 48678 to determine the number of
MPs in a sample) after accumulation of 5,000 gated
events.
FXa and prothrombinase formation and inhibition assays
The formation of intrinsic and extrinsic FXa and pro-
thrombinase in the presence of platelets and MPs was
performed as previously described [13]. For the intrinsic
FXase formation assays, 1 × 104 platelets or 10 μl of MP
suspension (prepared as described above) were incu-
bated with 1 nM FIXa, 130 nM FX, 0.2 nM thrombin,
and 5 nM FVIII in FXa buffer (1 ml 10 × TBS, 200 μl
10 % BSA, 8.8 ml ddH2O) at 25 °C for 5 min followed
by addition of EDTA (7 mM, final concentration) to stop
the reaction. Immediately after the addition of 10 μl
chromogenic substrate S-2765 (0.8 mM), production of
FXa was determined by measurement of absorbance at
405 nm on a Universal Microplate Spectrophotometer
(PowerWave XS, Bio-Tek, Winooski, VT, USA) in kin-
etic mode. The measurement lasted 15 min, and the
Table 1 Baseline characteristics of patients with colon cancer and healthy subjects at inclusion
Characteristics Healthy subjects (n = 33) Stage I (n = 16) Stage II (n = 47) Stage III (n = 28) Stage IV (n = 21)
Gender (Male, %) 17 (51.52 %) 6 (37.50 %) 29 (61.70 %) 12 (42.86 %) 8 (38.10 %)
Age (years) 60.72 ± 10.26 61.38 ± 11.71 63.51 ± 10.50 64.38 ± 9.99 58.86 ± 12.00
Albumin (g/l) 38.91 ± 4.87 33.96 ± 6.71 36.22 ± 6.22 36.99 ± 6.25 36.97 ± 4.62
Total cholesterol (mM) 3.96 ± 0.62 3.93 ± 1.14 3.85 ± 1.24 3.50 ± 0.89 3.48 ± 1.17
Triglycerides (mM) 0.94 ± 0.46 1.26 ± 0.35 1.37 ± 0.80 1.31 ± 0.66 1.67 ± 0.61
CEA (ng/ml) ND 2.13 (1.08-2.30) 4.73 (3.23-18.88)b 3.16 (2.55-7.18)b 10.54 (8.91-13.64)bcd
CA199 (U/ml) ND 9.45 (5.38-10.19) 15.76 (10.73-34.51)b 19.43 (10.67-46.56)b 64.07 (2.56-779.92)bcd
Platelet count (109/L) 248.35 ± 50.32 281.40 ± 94.95 259.62 ± 91.42 273.79 ± 87.21 309.97 ± 77.95
Erythrocyte count (1012/L) 4.35 ± 0.42 4.16 ± 0.71 4.43 ± 0.83 4.50 ± 0.59 4.23 ± 0.84
Hemoglobin (g/L) 126.49 ± 20.37 117.51 ± 32.60 123.81 ± 30.15 124.73 ± 27.60 120.23 ± 29.76
PT (s) 11.70 ± 0.72 10.83 ± 0.70 11.86 ± 0.92 11.26 ± 0.87 11.06 ± 0.81
APTT (s) 31.41 ± 2.85 27.14 ± 3.41a 27.84 ± 4.01a 25.39 ± 2.85abc 24.81 ± 2.56abc
D-dimer (mg/L) 0.13 (0.06-0.18) 0.31 (0.19-1.07)a 0.38 (0.22-1.78)a 0.72 (0.32-1.16)abc 0.73 (0.29-1.12)abc
Fibrinogen (g/L) 3.47 ± 1.03 3.59 ± 1.66 3.89 ± 1.19 3.42 ± 0.72 3.81 ± 0.58
Current smoking, n (%) 5 (15.15 %) 2 (12.50 %) 9 (19.15 %) 6 (21.43 %) 5 (23.81 %)
Thrombotic events, n (%) 2 (6.06 %) 3 (18.75 %)a 10 (21.28 %)a 9 (32.14 %)a 6 (28.57 %)a
Data are expressed by mean ± standard deviation [SD], percentage or median (interquartile range [IQR]). PT prothrombin time, APTT activated partial
thromboplastin time. ND not determined. aP < 0.05 versus healthy controls, bP < 0.05 versus stage I, cP < 0.05 versus stage II. dP < 0.01 versus stage III
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read interval was 11 s. Measurement of extrinsic FXa
formation was analogous to that for intrinsic FXa except
that cells or MPs were incubation with 130 nM FX, 1nM
FVIIa and 5 mM Ca2+. Each test was performed in tripli-
cate. Results were measured against the rate of substrate
cleavage of a standard dilution of FXa. The means of
generated FXa for all time points were analyzed.
In the prothrombinase formation assay, cells or MPs
were incubated with 1 nM FVa, 0.05 nM FXa in the
presence of 1 μM prothrombin and 5 mM Ca2+ in pro-
thrombinase buffer (1 × TBS with 0.05 % BSA) at 25 °C
for 5 min. After addition of EDTA and chromogenic
substrate S-2238 (0.8 mM), thrombin production was
assessed as described in the FXase formation assay. Re-
sults were evaluated against the rate of substrate cleav-
age from a dilution curve of thrombin. To test the
inhibition of coagulation complexes by lactadherin or
anti-TF antibody, the platelets or MPs-containing sus-
pension was preincubated with lactadherin (128 nM) or
anti-TF (40 μg/ml) for 10 min at 25 °C in Tyrode’s buf-
fer. The mixture was then incubated with the specified
clotting factors according to the above protocols. The
quantity of FXa or thrombin formation was assessed as
previously described [13, 24].
Coagulation time and fibrin formation and inhibition
assay of platelets and MPs
PCA of platelets and MPs was evaluated by one-stage recal-
cification time assay in a KC4A-coagulometer (Amelung,
Labcon, Heppenheim, Germany). One hundred μl of plate-
let (1 × 107) or MPs suspension (10 μl of MPs-enriched sus-
pension was resuspended in 90 μl Tyrode’s buffer) was
incubated with 100 μl of MP-free human plasma at 37 °C.
After 180 s, 100 μl of warmed 1.5 mM CaCl2 was added to
start the reaction and the clotting time was recorded.
All clotting assays were performed in triplicate. Based
on the previous analysis, we selected the stage IV of the
colon cancer patients to perform inhibition assays of
platelets and MPs. Fifty μl of lactadherin (128 nM) or
anti-TF (40 μg/ml) was added to 100 μl cells or MP
suspension, and then incubated for 10 min at 37 °C.
Clotting time was recorded after adding of 100 μl MP-
free human plasma and 50 μl of warmed 1.5 mM CaCl2
as mentioned above.
Fibrin formation was quantified by turbidity as de-
scribed [28]. Isolated platelets and MPs (as used in co-
agulation time assays) were added to re-calcified
(10 mM, final) MDP (88 % MDP, final) in the circum-
stance of MDP isolated from healthy donors in the pres-
ence or absence of lactadherin (128 nM) or anti-TF
(40 μg/ml). Fibrin formation was measured by turbidity
at 405 nm in a SpectraMax 340PC plate reader. Each
test was performed in triplicate.
Confocal microscopy
To evaluate and image PS exposure, platelets (colon can-
cer stage IV) were incubated with Alexa 488-lactadherin
(4 nM, final concentration) for 10 min at room
temperature in the dark, then washed to remove un-
bound dye, and imaged immediately. To observe the
contribution of MPs to fibrin formation in colon cancer
stage IV, MPs-containing suspensions (25 μl MPs was
washed twice and resuspended in 75 μl of Tyrode’s buf-
fer) were incubated with plasma (platelet poor plasma
centrifuged 106,000 g for 1 h at 4 °C) and 3 mM cal-
cium. Fibrin networks were imaged using laser confocal
microscopy in the presence of Alexa 647-conjugated
anti-fibrin. Background signal was calculated using a
similarly labeled isotype matched control antibody. Ob-
servation of the PS exposure on MPs labeled with Alexa
Fluor 488-lactadherin and Alexa Fluro 647-annexin V
was carried out by confocal microscopy as previously de-
scribed [13]. Images were obtained in using LSM 510
SYSTEM (Carl Zeiss Jena GmbH, Jena, Germany).
Statistical analysis
Numerical variables were tested for normal distribution
with the Kolmogorov-Smirnov test. Normally distributed
variables were summarized as mean (±SD) and com-
pared using one-way-ANOVA followed by Bonferroni’s
multiple comparison tests. Non-normally distributed
variables were summarized as medians with interquartile
ranges (IQR). Median values of clinical parameters and
MP count of healthy subjects and colon cancer groups
were compared using Kruskal-Wallis statistical test and
further analysed using Dunn’s multiple comparison test.
Frequencies were provided for all nominal values and
differences were calculated using Chi-square test.
Spearman’s rank correlation was run to determine the
relationship between the colon cancer metastasis and
PS+ platelets, MPs, PMPs, or EMPs levels, and between
clotting time and those PS+ cells and MPs levels. All
statistical analyses were carried out using Graph Pad
Prism (version 5.0) or SPSS 16.0 statistical software
package. P <0.05 was considered statistically significant.
Results
Subject characteristics
Clinical characteristics of healthy subjects (HS) and dif-
ferent stages of colon cancer patients are shown in
Tables 1. One hundred and twelve patients with colon
cancer, including 16 stage I, 47 stage II, 28 stage III and
21 stage IV, were investigated. For the 21 stage IV colon
cancer patients, 12 patients have liver metastasis, 7 pa-
tients lung metastasis, 1 patient brain metastasis and the
remaining one has bone metastasis. For each stage (I, II,
III, and IV), thrombotic events happened more fre-
quently in colon cancer patients than in healthy
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controls. In addition, the level of APTT in patients with
colon cancer stage III/IV were significantly lower than
those measured in stage I/II patients, with highest level
in healthy individuals, while D-dimer had an inverse
trend. Within subgroups of colon cancer patients, stage
IV patients had significantly higher level of CEA and
CA-199 than those in stage II/III, and lowest in stage I.
Compared with controls, different stages of colon
cancer patients had no significant difference in gender,
age, albumin, total cholesterol, triglycerides, platelet
and erythrocyte counts, hemoglobin, PT, fibrinogen and
current smoking. Moreover, we did not find positive rela-
tionships between MP levels and serum albumin, total
cholesterol, triglycerides and hemoglobin. Nevertheless, we
found a positive correlation between colon cancer
metastasis and PS+ platelets (r = 0.51, P = 0.003), MPs
(r = 0.27, P = 0.036), and PMPs levels (r = 0.39, P = 0.016)
but not EMPs (r = 0.79, P = 0.182), or TF+ MPs levels
(r = 0.54, P = 0.068).
PS+ platelet levels
We first measured the exposure of PS on the extracel-
lular membrane of blood platelets in healthy subjects
and colon cancer patients by flow cytometry. PS+ plate-
lets in two colon cancer patients with stage II and IV
respectively were shown in Fig. 1a and b. For each stage
(I, II, III, and IV), the plasma levels of PS+ platelets
[(100 ± 26) × 108/L, (109 ± 27) × 108/L, (204 ± 48) × 108/
L and (310 ± 51) × 108/L, respectively] were significantly
(P <0.001) higher in colon cancer patients than in HS
[(25 ± 8) × 108/L] (Fig. 1c). In addition, the plasma
levels of PS+ platelets in patients with cancer stage IV
were significantly (P <0.001) higher than those measured
in stage I, II, and III patients. Patients with stage III have
significantly (P <0.001) higher level of PS+ platelets than
those in stage I and II, but no statistic difference (P >0.05)
in PS+ platelets between stage I and II.
Origin of MPs and their levels
Total number of MPs and their phenotypic characterization
were tested. A known count of larger beads (TruCount
beads, Becton Dickinson) was used as an internal standard
enabling us to calculate the absolute number of MPs per
volume of specimen. For most study subjects, more than
90 % of events were PS positive as we previously described
[13]. PMPs, EMPs and TF MPs are defined as platelet,
endothelia and TF-derived MPs separately. MPs in colon
cancer patients can be originating from platelets and endo-
thelial cells (Fig. 2a and b).
Plasma levels of total PS+ MPs (lactadherin+ phenotype)
were significantly (P <0.001) increased in patients with
stage II, III, and IV [4405 (3402–5060) μl−1, 6525 (5579–
6932) μl−1, and 7203 (6625–7858) μl−1, respectively] as
compared with total PS+ MP levels measured in HS [2515
(1968–2977) μl−1] (Fig. 2c). Plasma levels of PS+ MPs ob-
served in stage I patients [4298 (3115–4806) μl−1] were
higher than those observed in HS, but with no significant
difference. Although plasma levels of PS+ MPs in stage IV
or III patients were significantly (P <0.001) higher than
those in stage I or II, we did not found any significant dif-
ference between stage I and II (P >0.05), and between
stage III and IV (P >0.05). PMPs (CD41a+ phenotype) had
a similar trend. Plasma levels of PS+ PMPs in stage IV
[1779 (1573–1992) μl−1] or III [1027 (861–1192) μl−1]
patients were significantly (P <0.001) higher than those
in HS [611 (457–839) μl−1], stage I [649 (567–744) μl−1],
or II [696 (549–771) μl−1], but we did not found any sig-
nificant difference between stage I and II (P >0.05), and
between stage III and IV (P >0.05) (Fig. 2d).
Fig. 1 Phosphatidylserine (PS) exposure on platelets. Isolated platelets were incubated with Alexa Fluro 488-lactadherin separately in the dark for
10 min at room temperature before flow cytometric analysis. A representative set of histograms is shown to illustrate lactadherin-positive (PS+)
platelets from (a) one stage II patient with colon cancer, and (b) one stage IV patient. c Comparison of PS+ platelets among healthy subjects
(n = 33), and colon cancer patients in different stage (stage I: n = 16, II: n = 47, III: n = 28, or IV: n = 21). Data displayed are mean ± SD. ***P <0.001
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Plasma levels of EMPs (CD31+CD41a− phenotype)
were significantly (P <0.01) increased in patients with
stage II, III, and IV [245 (178–282) μl−1, 394 (325–425)
μl−1 and 547 (504–597) μl−1, respectively] as compared
with those measured in HS [18 (7–38) μl−1] (Fig. 2e).
Plasma levels of EMPs observed in HS were lower than
those observed in stage I patients [140 (87–184) μl−1],
but with no significant difference (P >0.05). TF+ MPs
(CD142+ phenotype) in patients with stage I, II, III and
IV [66 (48–74) μl−1, 87 (61–96) μl−1, 157 (130–169) μl−1
and 200 (181–214) μl−1, respectively] had significantly
(P <0.05) higher levels than those in HS [18 (14–22) μl−1]
(Fig. 2f). Plasma levels of both EMPs and TF+ MPs in
patients with stage III or IV were significantly (P <0.01)
higher than those in patients with stage I or II, respect-
ively. EMPs and TF+ MPs levels did not significantly differ
between colon cancer patients stage I and II (P >0.05), and
between patients stage III and IV (P >0.05).
Formation and inhibition assays of procoagulant enzyme
complexes of platelets and MPs
Consistent with the above finding of increased PS expos-
ure on platelets and MPs, these entities also demon-
strated heterogeneous levels in intrinsic/extrinsic FXa
and thrombin production (Fig. 3). Platelet intrinsic FXa,
extrinsic FXa, and thrombin were significantly (P <0.001)
Fig. 2 Number and origin of MPs by flow cytometry analyses in study subjects. A representative set of scattergrams in two samples from colon
cancer patients is shown to illustrate MPs and subpopulation definitions. Lactadherin-positive MPs were examined for expression of other antigens by
co-labeling with Alexa Fluor 488- and Alexa Fluor 647-labeled antibodies as is shown here for platelet-derived MPs (Alexa Fluro 488-CD41a+) and
endothelia-derived MPs (Alexa Fluro 647-CD31+/Alexa Fluor 488-CD41a−) in (a) stage II or (b) IV of colon cancer patients. Comparison of c PS+ total
MPs, d platelet-derived MPs (PMPs), e endothelial-derived MPs (EMPs), and f tissue factor-positive MPs (TF+ MPs) among healthy subjects (n = 33), stage
I (n = 16), II (n = 47), III (n = 28), or IV (n = 21) colon cancer patients. Data are given as median (horizontal bar), 25th and 75th percentile (boxes), and
10th and 90th percentile (error bar). *P <0.05; **P <0.01; ***P <0.001
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higher in all stages of colon cancer patients than in HS
(Fig. 3a-c). The production of the three-procoagulant en-
zyme complexes in platelets was significantly (P < 0.001)
increased in patients with cancer stage IV compared
with stage I, II, and III patients respectively. In addition,
patients with stage III have obviously higher (P <0.001)
level of platelet intrinsic and extrinsic FXa, and throm-
bin than those measured in stage I or II, but no statistic
difference between stage I and II (P >0.05). MP FXa and
thrombin were significantly (P <0.001) increased in pa-
tients with stage II, III, and IV as compared with that
measured in HS (Fig. 3a-c). The three procoagulant en-
zyme complexes of MPs observed in stage I patients
were higher (P <0.001) than those observed in HS, but
with no significant difference (P >0.05). Although MP
FXa and thrombin in stage IV or III patients were higher
than those in stage I or II (P <0.001), we did not found
any significant difference between stage I and II
(P >0.05), and between stage III and IV (P >0.05).
To determine the necessity of exposed PS and TF on
platelets and MPs to support procoagulant reactions, we
performed the PCA inhibition assays using platelets and
MPs from colon cancer patients with stage IV which had
the most large amount of PS+ platelets or MPs. FXase
and prothrombinase inhibition assays were performed
with 128 nM lactadherin or 40 μg/ml anti-TF as we pre-
viously described [13]. The intrinsic FXa, extrinsic FXa
and thrombin production for platelets were reduced by
84 %, 81 % and 85 %, and MPs by 79 %, 77 % and 83 %,
when lactadherin were added (Fig. 3d). Meanwhile, the
extrinsic FXa for platelets and MPs were reduced by
57 % and 64 % resperively when anti-TF antibody was
included. Thus, lactadherin blocks procoagulant enzyme
complex generation greater than anti-TF antibody.
Coagulation and fibrin formation and inhibition assays of
platelets and MPs
The PCA of platelets and MPs was further assessed by
recalcification-time assays in the study subjects
(Fig. 4a). Platelets isolated from each stage of colon
cancer patients had markedly shortened clotting time
(P <0.05), compared with equal numbers of cells from
control subjects. The coagulation time of MPs signifi-
cantly (P <0.05) decreased in stage II, III and IV when
Fig. 3 Procoagulant enzyme complexes formation and inhibition assays. a Intrinsic FXa, b extrinsic FXa, and c thrombin production of platelets
and MPs from healthy subjects (n = 33), stage I (n = 16), II (n = 47), III (n = 28), or IV (n = 21) colon cancer patients were evaluated. Intrinsic FXa
formation was measured in the presence of FIXa, FVIII and thrombin. Extrinsic FXa production was assessed in the presence of FVIIa. Thrombin
generation was investigated in the presence of FXa and FVa. d The capacity of lactadherin (128 nM) to block procoagulant enzyme complexes on
platelets and MPs from 21 patients stage IV was evaluated. lactadherin decreased activity of the procoagulant enzyme complexes by approximately
80 % in platelets. Data displayed are mean ± SD. *P <0.001. In-Xa: intrisic FXa; Ex-Xa: extrisic FXa; lact: lactadherin
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compared to that in HS. Platelets and MPs coagulation
time were significantly (P <0.05) short in patients with
stage III or IV in comparison to stage I or II. Add-
itionally, platelet coagulation time in stage IV were
shorter (P <0.05) than those in stage III. However, no
significant difference was found in stage III comparing
to stage IV of MPs (P >0.05), and in stage I comparing
to stage II on coagulation time of platelets and MPs
(P >0.05). We found an inverse correlation between
clotting time and PS+ platelets (r = −0.81, P = 0.027),
MPs (r = −0.74, P = 0.036), and PMPs levels (r = −0.69,
P = 0.043) in patients. However, there was no correlation
between clotting times and EMPs (r = −0.84, P = 0.062), or
TF+ MPs levels (r = −0.64, P = 0.059).
To determine the necessity of exposed PS and TF on
platelets and MPs to support coagulation time, we per-
formed the coagulation inhibition assays. Treatment
with lactadherin prolonged coagulation time of platelets
and MPs to the extent of healthy controls, whereas anti-
TF did not significantly affect the coagulation times
(Fig. 4b). We further evaluated the ability of platelets
and MPs to support fibrin formation using turbidity
measurements. Platelets or MPs isolated from colon
cancer stage IV resulted in significant fibrin production
compared to controls. Lactadherin markedly inhibited fi-
brin formation, whereas anti-TF antibody did not signifi-
cantly affect fibrin formation (Fig. 4c and d). These data
indicate platelets and MPs trigger PS-dependent fibrin
production.
Confocal microscopy
PS+ platelets, MPs and fibrin at colon cancer stage IV
were imaged using fluorescence labeled lactadherin
(green, Alexa 488), annexin V (red, Alexa 647) and anti
fibrin antibody (red, Alexa 647) by laser confocal mi-
croscopy. Platelets in healthy individuals were rarely la-
beled with green fluorescence (Fig. 5a), but platelets
from patients stage IV were detected obvious green
fluorescence suggesting strong PS exposure (Fig. 5b,
arrowhead). Meanwhile, those PS+ platelets were releas-
ing small vesiculous and PMPs were shedding from their
parent platelets (Fig. 5b, triangles). In colon cancer pa-
tients stage IV, large quantities of MPs were generated in
the blood samples with extensive exposure of PS as indi-
cated by labeling with both lactadherin (green) and
annexin V (red) generating co-localized yellow fluores-
cence (Fig. 5c). Because cellular PCA dictates fibrin clot
formation, we sought to explore whether MPs had a
similar effect. MPs isolated from patients stage IV were
incubated with normal MDP and fibrin formation was
evaluated by red fluorescence anti fibrin antibody. We
observed strikingly abundant fibrin spread around MPs,
and this resulted in fibrin network formation (Fig. 5d).
Fig. 4 Coagulation and fibrin formation and inhibition assays. a Coagulation times of platelets and microparticles (MPs) from healthy subjects
(n = 33), stage I (n = 16), II (n = 47), III (n = 28), or IV (n = 21) colon cancer patients were measured. b Coagulation time of platelets and MPs in 21
stage IV colon cancer patients was detected in the absence or presence of lactadherin (128 mM) or anti-TF (25.6 μg/ml). Fibrin production on
c platelets or d MPs was detected in the presence of recalcified MDP with or without 128 nM lactadherin or 25.6 μg/ml anti-TF. Data displayed
are mean ± SD. *P <0.05
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Discussion
Our study demonstrated that plasma levels of circulating
PS+ platelets and MPs were significantly higher in colon
cancer patients with stage I/II/III/IV and stage II/III/IV
than in controls, respectively. PMPs and EMPs were sig-
nificantly increased in stage III/IV and in stage II/III/IV
patients, respectively. In addition, we showed that plate-
lets in all stages of colon cancer patients and MPs in
stage II/III/IV had higher intrinsic/extrinsic FXa and
thrombin production, and shorter coagulation time than
ones from healthy subjects. Fibrin formation of platelets
and MPs from colon cancer stage IV was higher than
that from healthy individuals. The PCA can be success-
fully blocked by binding of lactadherin to PS on platelets
and MPs. These results therefore indicate that PS+ plate-
lets and MPs play important role in the hypercoagulable
state of colon cancer patients with different stage.
To our knowledge, this is the first study to evaluate
the role of PS+ platelets in colon cancer patients. PS is
normally present on the cytoplasmic leaflet of quiescent
cells, with virtually none on the exofacial leaflet [10].
Changing this resting distribution of PS has a strong po-
tential for initiating signaling and was first recognized in
the case of platelet activation [9]. Our data showed that
PS+ platelets were gradually increased from colon cancer
stage I to IV. Dymicka et al. showed that patients suffer-
ing from colon cancer had high levels of platelet CD62P
expression and soluble P-selectin concentration, sup-
porting our findings [14]. Indeed platelet activation and
thrombocytosis have been previously reported in those
patients and is associated with poor survival [29, 30].
PMPs, as a product of platelet activation, significantly in-
creased in advanced colon cancer patients in our current
study. In contrast to our results, another study showed
that the amount of CD41a+ PMPs did not significantly
differ between patients and controls [19]. However, their
report was based on a population of less than 20 colon
cancer patients and annexin V was used to detect PMPs.
Annexin V has been reported to be a less effectively and
sensitively probe to detect PS-rich cells and MPs than
lactadherin [22, 23]. Moreover, our confocal photomi-
crographs of MPs showing strong lactadherin staining
and rare annexin V staining further strengthen this.
High-grade disease is associated with a considerably
increase of nodal and distant metastasis [31]. Patients
with stage III/IV were present with enhanced metastasis
rate and also have markedly higher levels of PS+ platelets
and PMPs compared with patients with stage I/II. The
exact mechanisms inducing increased levels of PS+
platelets and the formation of PMPs in colon cancer are
Fig. 5 PS exposure on platelets and MPs and fibrin formation was evaluated using fluorescence confocal microscopy. a Platelets from healthy
subjects barely marked with green fluorescence, b while platelets from colon cancer stage IV were labeled with lactadherin (green fluorescence,
arrowhead) and PMPs (triangles) were shedding from PS exposed platelets. c MPs were strongly labeled with both Alexa 488-lactadherin (green)
and Alexa 647-annexin V (red) indicating extensive PS exposure. d Fibrin labeled with red fluorescence was observed along with PS+ MPs labeled
with lactadherin (green). Representative image; scale bars represent 10 μm (b) or 5 μm (c and d)
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not well understood, but it seems that there is a relation-
ship with platelet-tumor cell cross-talk. The colon can-
cer cells line can bind to activated platelets, stimulate
powerful platelet aggregation, and promote platelet se-
cretion [32, 33]. This may partly lead PMPs shedding
from the PS+ or activated platelets. PMPs in this study
were shedding from PS+ platelets may further explain
this phenomenon. High plasma level of PS+ platelets in
colon cancer patients may have the capacity to contrib-
ute to different stages of cancer progression and metas-
tasis since activated platelets play an important role in
neoplasm angiogenesis, invasion, survival in circulation
and metastasis [15, 34–36]. Intriguingly, our results
showed that the plasma level of PMPs did not exhibit a
tendency analogous to the level of PS+ platelets but that
levels of PS+ platelets and PMPs were both correlated
with colon cancer metastasis. Although the angiogenic
potential of PMPs is as important as the angiogenic po-
tential of platelets [37, 38], the function of high PMPs
levels in advanced colon cancer are still needed to be ex-
plored and verified in large population based studies in
the future.
High levels of EMPs have been reported in cardiovas-
cular diseases, autoimmune diseases, but not in colon
cancer [39, 40]. Our results showed that EMPs increased
in colon cancer patient stage II/III/IV but not in stage I.
This may due to enhanced tumor spread and angiogen-
esis in higher-grade colon cancer compared with stage I.
The major mediators of tumor angiogenesis are the vas-
cular endothelial growth factor (VEGF) family and its re-
ceptors, which have been reported to be closely involved
in colon cancer stage II/III/IV [41–43]. VEGF stimula-
tion activates endothelial proliferation, and promotes
tumor cell-associated, vessel-mediated and immuno-
inflammatory processes in colon carcinoma during
which enhanced EMPs would be released [42]. Interest-
ingly, we found that the levels of EMPs were not corre-
lated to coagulation time in colon cancer patients,
suggesting that increased levels of EMPs in the patients
may have their unique role in those patients. Several
studies have shown the involvement of EMPs at different
stages of angiogenesis, including matricial degradation,
recruitment and differentiation of endothelial progeni-
tors, and proliferation and migration of endothelial cells
[44]. Thus, high levels of EMPs may be involved in colon
cancer angiogenesis.
TF has been commonly regarded as one of the import-
ant procoagulant substance, which was correlated with
the risk of thrombosis in cancer patients such as pancre-
atic cancer [20]. Here, we reported that colon cancer pa-
tients have an increased plasma level of TF+ MPs.
Previous study showed that high levels of TF+ MPs in
advanced colon cancer patients, supporting our results
[19]. In the present study, TF+ MPs were also over-
expressed in colon cancer stage I. This augment may at
least in part due to colon cancer-derived TF+ MPs, since
tumor-derived MPs are critical sources of TF in cancer
and human TF antigen has been demonstrated to be re-
leased into the blood from human colon tumor [17, 45,
46]. Increased MP TF activity has been detected in colon
cancer patients [20]. However, we found that anti-TF
antibody did not significantly prolong the clotting time
of MPs, and further coagulation and fibrin inhibition as-
says suggest that PS+ platelets and MPs seems to be the
main source of excessive PCA in colon cancer patients.
One possible explanation is that plasma-exposed TF is
frequently encrypted with little or no detectable PCA
and is decrypted through the availability of clusters of
PS [21]. Moreover, our finding is also supported by our
previous studies showing that the expression of activated
TF overlaps with PS exposure and TF-dependent FXa
generation was decreased after blocking PS [13, 47].
Hypercoagulability is well documented in all types of
cancers, and is the second leading cause of death in can-
cer patients [48]. Here we demonstrate a hypercoagula-
ble state that is associated with increasing levels of PS+
platelets and MPs in those patients. PS exposure on
platelets and MPs provides binding sites for FXa, sup-
ports thrombin generation, results in fibrin formation,
and processes blood clotting [9, 10]. Our data demon-
strated a statistically significant difference between colon
cancer patients and healthy subjects regarding the pro-
coagulant enzyme complexes, fibrin formation and co-
agulation time of platelets and MPs. We also observed
an inverse correlation between PS+ platelets, MPs and
PMP levels and the clotting time measured by the func-
tional coagulation time test. PS blockage by lactadherin
lengthens the coagulation time and reduced fibrin for-
mation to control levels, and inhibited their intrinsin/ex-
trinsic FXa and thrombin production about 80 %. Taken
together, these results strongly reflect that functional
PCA of circulating platelets and MPs that is linked to
the PS present at the platelet or MP surface.
In colon cancer patients, PCA of platelets and MPs
has the similar trend to the level of PS+ platelets and
MPs separately, which is inconsistent with our previous
reports that high PS+ platelets had relative high PCA
[12, 13]. In our current study, PCA of MPs was slightly
higher in patients with stage II colon cancer patients,
and obviously augmented in stage III/IV or advanced
stage colon cancer. However, Van Doormaal et al. re-
ported that MP phospholipid-dependent PCA was not
different between cancer patients and healthy controls
[49], but they did not account for the effect of disease
stage. The PCA of MPs in stage I patients and healthy
controls was similar to those in our study. The PCA of
MPs has been reported to be higher in patients with ad-
vanced stage breast cancer than in healthy subjects [50],
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supporting our results. In addition, in cutaneous malig-
nant melanoma, the PCA of MPs not only increased in
stage III/IV, but also in stage II [51]. Thus, PCA of MPs
makes contribution to hypercoagulable state in cancer
patients depending on tumor classification and tumor
types. Nevertheless, we can’t rule out other variables
such as tumor site or size and these factors need to be
further evaluated in colon cancer patients.
There are currently controversies about the antiplate-
let treatment of colon cancer patients. Although low-
dose aspirin usage after diagnosis of colon cancer did
not increase survival time [52], but evidence from ran-
domized controlled trials and meta-analysis of aspirin,
to prevent vascular events, indicates that post diagnosis
aspirin therapy may improve colon cancer overall sur-
vival, and reduce both all cause and colon cancer spe-
cific mortality [53–56]. Furthermore, proximal colon
cancer patients have been reported to be greatest bene-
fit for long-term effect of aspirin. Our data suggests
that high level of PS exposure on platelets and MP is
associated with increased PCA in different stage of
colon cancer patients. It seems crucial to block PS, as
well as FXa and thrombin, to prevent the activated
blood coagulation of platelets and MPs. Antiplatelet
treatment is not sufficient to entirely prevent PCA ac-
tivity in stage II/III/IV since there is a significantly high
level of MPs and MP-associated PCA especially in ad-
vanced colon cancer. Thus, the administration of both
anticoagulant and antiplatelet therapy seems to be ne-
cessary. The results from this study suggest that future
research should focus on discovery and development of
direct PS inhibitors.
In our study, we only investigated PS+ platelets, MPs,
PMPs, and EMP and we cannot exclude the increased
PS exposure on other cells or the presence of MPs from
other cell origin, that is, inflammatory, immune, or
tumor cells. Furthermore, considering the small popula-
tion of study subjects, we are unable to conclude that PS
+ platelets or MPs or their PCA can be used a biomarker
of risk in these patients. Prospective large cohort studies
are underway to confirm the exact role or value of PS+
cells or MPs in colon cancer patients. In conclusion, this
study demonstrates high levels of circulating PS+ plate-
lets, MPs, PMPs, EMPs and TF+ MPs in colon cancer
patients in association with a significant increased PCA.
Further studies are required to assess both the prognosis
and the thrombogenic value of PS+ cells and MP levels
in these patients and to determine whether these cells or
MPs can also originate from other cell types.
Conclusion
Collectively, our results show that PS platelets and mi-
croparticles promote PCA in colon cancer patients and
may unveil a potential therapeutic target to prevent
coagulation in those patients.
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